A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

NCT07431216 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma (GBM)

Interventions

DRUG: STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.
DRUG: Spironolactone (drug)

Sponsor

Starlight Therapeutics Inc.